October 16, 2012

SAGE® Labs, Ekam Imaging, Inc. Partner to Develop Preclinical Imaging Assays to Screen Therapies of Neurodegenerative Disease
Sigma-Aldrich® Corporation (SIAL) today announced that Sigma Advanced Genetic Engineering (SAGE) Labs, an initiative of Sigma® Life Science, and Ekam Imaging, Inc. have partnered to develop a suite of preclinical services based on the advanced translational power of genetically engineered rat models from SAGE Labs and Ekam’s expertise in functional magnetic resonance imaging (fMRI) technology.

February 08, 2012

PsychoGenics Expands its In Vivo Capabilities with the Addition of Preclinical Magnetic Resonance Imaging Technology Services in Partnership with Ekam Imaging
PsychoGenics Inc. and Ekam Imaging, Inc., announced the establishment of an alliance to provide Ekam’s specialized imaging services in awake animals to complement PsychoGenics’ testing capabilities and drug discovery services. Ekam is the only service organization performing multimodal imaging, including functional Magnetic Resonance Imaging (fMRI) and pharmacological MRI (phMRI) on conscious animals.

September 22, 2011

Ekam Imaging with partners is hosting imaging symposium on 22 September, 2011 at Northeastern University Campus

February 28, 2011

Biotrofix and Ekam Imaging Release: Strategic Alliance between Research Firms Will Combine Expertise in CNS and Vascular Disease Models with Translational, Multi-Modal Imaging
Boston, MA – Aiming to minimize risk from preclinical development, Biotrofix and Ekam Imaging announced this month they have entered into a partnering agreement together to provide synergistic capabilities to the pharmaceutical and biotechnology industries. The goal of the partnership is to deliver high-quality, accurate and translatable data that greatly assists their sponsors by allowing them to make faster and better- informed decisions.

March 11, 2010

Ekam Imaging Inc. Announces Commercialization of Imaging Technology to Support Drug Discovery and Development for Central Nervous System Diseases
(Shrewsbury and Boston, MA) — In a significant breakthrough in assisting early-stage drug development, especially for Central Nervous System (CNS) diseases and conditions such as Alzheimer’s and Parkinson’s Disease, Schizophrenia and Post Traumatic Stress Disorder (PTSD), Ekam Imaging Inc. is pleased to announce a new service offering positioned to transform the way in which new therapies are discovered and developed. Ekam is the only Contract Research Organization (CRO) now capable of performing translatable, multi-modal imaging studies (fMRI and molecular) using awake, unanesthetized animals.

March 01, 2010

Awake Animal Imaging and Analysis Mark Nedelman, President, Ekam Imaging Inc., Shrewsbury and Boston, Mass. Drug Discovery & Development
A major limitation of current non-clinical imaging-especially relating to the brain-is that animals must be anesthetized.1 This creates a significant gap in the ability to provide serial data in diseases affecting the brain and for new and existing drugs focused on the central nervous system (CNS). With the advent of functional magnetic resonance imaging (fMRI) in awake animals, it is now possible to resolve changes in or patterns of neuronal activity across the entire brain with exquisite spatial and temporal resolution by evaluating a change in blood oxygen level dependent (BOLD) measurements.2 Synchronized changes in neuronal activity across different regions of the brain can be viewed as functional neuroanatomical circuits coordinating the thoughts, memories, and emotions for particular behaviors.